Vmn1r125 Activators
Vomeronasal 1 Receptor 125 Activators are known to influence various signaling cascades that can lead to the enhanced activity of vomeronasal 1 receptor 125. Chemicals like L-Arginine and Ginsenoside Rg3 foster the synthesis of nitric oxide, which stimulates guanylyl cyclase to elevate cGMP levels, thus potentially enhancing the activity of vomeronasal 1 receptor 125 through cGMP-dependent protein kinase (PKG) signaling. Sildenafil and Zaprinast, by inhibiting phosphodiesterase 5, prevent the degradation of cGMP, thus maintaining high levels of this secondary messenger and sustaining PKG activity. Through this mechanism, PKG can phosphorylate various targets within cells that are likely to be involved in vomeronasal 1 receptor 125 signaling pathways.
Compounds like Forskolin and Isoproterenol increase intracellular cAMP, indirectly activating PKA, which is known to phosphorylate proteins within signaling pathways related to vomeronasal 1 receptor 125. Caffeine and IBMX, by inhibiting phosphodiesterases, also raise cAMP and cGMP concentrations, thus indirectly enhancing PKA and PKG signaling pathways, which may affect vomeronasal 1 receptor 125 activity. Nicotine, through the activation of nicotinic acetylcholine receptors, causes depolarization and an increase in intracellular calcium, which can activate calcium-dependent signaling pathways indirectly enhancing the activity of vomeronasal 1 receptor 125. Similarly, the action of calcium channel blockers such as Nifedipine and Amlodipine on intracellular calcium levels can influence signaling cascades that enhance the function of vomeronasal 1 receptor 125. Yohimbine, through its antagonistic effects on alpha-2 adrenergic receptors, increases the release of norepinephrine, which then activates adenylate cyclase, subsequently raising cAMP levels and activating protein kinase A (PKA). The activation of PKA can lead to the phosphorylation of target proteins within various signaling pathways, which can indirectly influence the activity of vomeronasal 1 receptor 125.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
L-Arginine | 74-79-3 | sc-391657B sc-391657 sc-391657A sc-391657C sc-391657D | 5 g 25 g 100 g 500 g 1 kg | $20.00 $31.00 $61.00 $219.00 $352.00 | 2 | |
L-Arginine is a precursor for nitric oxide synthesis, which can activate guanylyl cyclase and increase cGMP levels. Elevated cGMP can enhance the signaling of vomeronasal 1 receptor 125 by increasing cGMP-dependent PKG activity. | ||||||
Caffeine | 58-08-2 | sc-202514 sc-202514A sc-202514B sc-202514C sc-202514D | 50 g 100 g 250 g 1 kg 5 kg | $33.00 $67.00 $97.00 $192.00 $775.00 | 13 | |
Caffeine inhibits phosphodiesterases, resulting in increased levels of cAMP and cGMP. This can enhance PKA and PKG activity, which may indirectly activate vomeronasal 1 receptor 125 through phosphorylation events. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a nonspecific inhibitor of phosphodiesterases, leading to elevated cAMP and cGMP levels. This can enhance PKA and PKG activity, potentially resulting in indirect activation of vomeronasal 1 receptor 125. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a beta-adrenergic agonist that can increase cAMP levels through adenylate cyclase activation. This can enhance PKA activity, which might indirectly activate vomeronasal 1 receptor 125. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits phosphodiesterase 5, leading to increased cGMP levels. This can enhance PKG activity, which may lead to indirect activation of vomeronasal 1 receptor 125. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Yohimbine blocks alpha-2 adrenergic receptors, which leads to increased release of norepinephrine and subsequent activation of adenylate cyclase. The rise in cAMP levels can indirectly activate vomeronasal 1 receptor 125. | ||||||
Nifedipine | 21829-25-4 | sc-3589 sc-3589A | 1 g 5 g | $59.00 $173.00 | 15 | |
Nifedipine is a calcium channel blocker that can alter calcium signaling. By modulating intracellular calcium levels, it can indirectly influence pathways that enhance the activity of vomeronasal 1 receptor 125. | ||||||
Amlodipine | 88150-42-9 | sc-200195 sc-200195A | 100 mg 1 g | $74.00 $166.00 | 2 | |
Amlodipine, a calcium channel blocker, can modulate intracellular calcium levels. This modulation can lead to the activation of signaling cascades that indirectly enhance vomeronasal 1 receptor 125 activity. | ||||||